JorgeCastilloMD

PubMed

• 2 citations
  Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
  Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee
  Blood Advances. 2024-04-09
• 7 citations
  Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
  Jorge J Castillo, Andrew R Branagan, David Sermer, Catherine A Flynn, Kirsten Meid
  Blood. 2024-02-15
• 1 citations
  Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing.
  Ali AlJabban, Henry Paik, Jon C Aster, Nancy Berliner, Jennifer Brouillard
  JCO Oncology Practice. 2024-02-01

Journal Articles

• TP53 Mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinaemia  
  Toni Dubeau, Steven P Treon, Jorge J Castillo, Christopher J Patterson, British Journal of Haematology
• Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom Macroglobulinemia  
  Ghobrial IM, Redd R, Armand P, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro A, Noonan K, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Well..., Leukemia, 1/3/2015
• Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials  
  Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL,Larson RA, Stone RM, American Journal of Hematology, 1/3/2015
• Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma  
  Castillo JJ, Reagan JL, Sikov WM, Winer ES, British Journal of Haematology, 1/1/2015
• Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbaz...  
  Castillo JJ, Bower M, Bruhlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cool..., Cancer, 1/1/2015
• Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database  
  Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP, British Journal of Haematology, 1/1/2015
• Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia  
  Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobri..., New England Journal of Medicine, 1/1/2015
• CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options  
  Castillo JJ, Chavez JC, Hernandez-Ilizaliturri FJ, Montes-Moreno S, Expert Review of Hematology, 1/1/2015
• The biology and treatment of plasmablastic lymphoma  
  Castillo JJ, Bibas M, Miranda RN, Blood, 1/1/2015
• Survival trends in Waldenstrom Macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database  
  Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP, Blood, 1/1/2014
• Improving the accuracy in prognosis for Burkitt lymphoma patients  
  Castillo JJ, Nadeem O, Expert Review on Anticancer Therapy, 1/1/2014
• Isotype-specific inhibition of the phosphatidylinositol-3- kinase pathway in hematologic malignancies  
  Castillo JJ, Iyengar M, Kuritzky B, Bishop KD, Onco Targets and Therapy, 1/1/2014
• Obesity Is Associated With Increased Relative Risk of Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Observational Studies  
  Castillo JJ, Ingham RR, Reagan JL, Furman M, Dalia S, Mitri J, Clinical Lymphoma Myeloma & Leukemia, 1/1/2014
• Carfilzomib, rituximab and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's Macroglobulinemia  
  Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ, Blood, 1/1/2014
• Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies  
  Castillo JJ, Reagan JL, Bishop KD, Apor E, British Journal of Haematology, 1/1/2014
• Sites of extranodal involvement are prognostic in patients with 
diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology ...  
  Castillo JJ, Winer ES, Olszewski AJ, American Journal of Hematology, 1/1/2014
• Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology and End Results database  
  Castillo JJ, Winer ES, Olszewski AJ, Cancer, 1/1/2013
• Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: A meta-analysis of 24 observational studies  
  Castillo JJ, Dalia S, Leukemia and Lymphoma, 1/1/2012
• Prognosis in primary effusion lymphoma is associated with the number of body cavities involved  
  Castillo JJ, Shum H, Lahijani M, Winer ES, Butera JN, Leukemia and Lymphoma, 1/1/2012
• CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the 
treatment of lymphoid malignancies  
  Castillo JJ, Furman M, Winer ES, Expert Opinion on Investigational Drugs, 1/1/2012
• Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies  
  Castillo JJ, Echenique IA, American Journal of Hematology, 1/1/2012
• The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP  
  Castillo JJ, Beltran BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN, Leukemia Research, 1/1/2012
• Diagnosis and management of hyponatremia in cancer patients  
  Castillo JJ, Vincent M, Justice E, The Oncologist, 1/1/2012
• Not all aggressive adult T-cell leukemia/lymphoma subtypes are created equal  
  Castillo JJ, Beltran BE, Journal of Clinical Oncology, 1/1/2012
• No association between cigarette smoking and incidence of 
plasma cell myeloma: A meta-analysis of 17 observational studies  
  Castillo JJ, Dhami P, Curry S, Brennan K, American Journal of Hematology, 1/1/2012
• Join now to see all

Books/Book Chapters

• Non-Hodgkin Lymphoma: Models, Prognostic Factors and Targets 
  Chapter: Prognostic factors in HIV-associated lymphoma 
  Page 153 - 169Layton JL, Castillo JJEditors: Quesenberry PJ, Castillo JJ.Springer Science + Business Media, New York, NY2013
• Non-Hodgkin Lymphoma: Models, Prognostic Factors and Targets 
  Chapter: Prognostic factors in T-cell lymphoma 
  Page 141 - 152Beltran BE, Castillo JJEditors: Quesenberry PJ, Castillo JJ.Springer Science + Business Media, New York, NY2013
• Abeloff's Clinical Oncology 
  Chapter: Special Issues in Pregnancy 
  Page 914 - 925Castillo JJ, Rizack TEditors: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper J.Elsevier, Philadelphia, PAEdition 5th,2012
• Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics 
  Chapter: EBV-positive diffuse large B-cell lymphoma of the elderly 
  Page 83 - 98Castillo JJEditors: Tao J, Sotomayor E.Springer Science + Business Media, Dordrecht, Netherlands2012
• Plasmablastic Lymphoma: An Emergent Disease with Poor Prognosis 
  Castillo JJVDM Verlag Dr, Mueller, Saarbrucken2010
• Join now to see all

Abstracts/Posters

• Assessment of Different Biological Variables (Serum Albumin, _-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a...
  Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 M...
  Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study ...
  Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Gro...
  Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells
  Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Stu...
  Jorge J Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical characteristics of rituximab intolerance in patients with Waldenstrom macroglobulinemia
  Kanan S, Meid K, Treon SP, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2014
• Incidence and survival outcomes of secondary malignancies among survivors of Waldenstrom macroglobulinemia
  Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter, ZR, Treon SP, Blood (ASH Annual Meeting Abstracts), 1/1/2014
• Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab- Containing Regimen: A Brown University O...
  Castillo JJ, Winer ES, Butera JN, Lansigan F, Rosati K, Safran H, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Intensity Of Smoking Increases The Odds Of Acute Myeloid Leukemia In Adult Smokers
  Fircanis S, Merriam P, Khan N, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory 
Wald...
  Ghobrial IM, Redd RA, Matous J, et al, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom Macroglobulinemia (WM)
  Siegel DS, Kaufman JL, Raje NS, et al, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Higher body mass index is associated with an increased risk of diffuse large B-cell lymphoma
  Castillo JJ, Ingham RR, Reagan JL, Dalia S, Furman M, Nemr S, Merhi B, Mitri J, Lymphoma & Myeloma, New York, NY, 1/25/2012
• Survival of newly diagnosed T-cell lymphoma in the modern era: Investigation of prognostic factors with critical examination of therapy in a multicenter US cohort
  Evens AM, Feldman T, Kroll A, Mully LS, Winer ES, Flowers C, Lansigan F, Nabhan C, Nastoupil L, Kim A, Li X, Waksmundzki K, Lam D, Draper JT, Meilleur A, Nath R, Cygan..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Monocytosis as prognostic factors in aggressive, non-primary cutaneous peripheral T-cell lymphoma: A study of 251 cases
  Beltran BE, Cotacallapa E, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Survival and clinicopathological characteristics of EBV-positive 
diffuse large B-cell lymphoma
  Beltran BE, Cotacallapa E, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Survival outcomes in marginal zone lymphomas in the rituximab era - analysis of the surveillance, epidemiology, and end results (SEER) database
  Castillo JJ, Olszweski AJ, Journal of Clinical Oncology, 1/1/2012
• Prognostic factors in patients with HIV-associated Hodgkin lymphoma: An analysis of 199 cases
  Furman M, Abramson JS, Beltran BE, Bibas M, Bower M, Collins J, Connors JM, Cwynarski K, Nguyen ML, Ribera JM, Tanaka PY, Vose JM, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2012
• R-CHOP versus CHOP in HIV-associated lymphoma: A meta-analysis of prospective studies
  Echenique I, Castillo JJ, 13th International Congress of Malignancies in AIDS and Other Acquired Immunodeficiencies, Bethesda, MD, 1/7/2011
• HIV-associated plasmablastic lymphoma: A multi-institutional study
  Furman M, Balsalobre P, Beltran BE, Bibas M, Bower M, Chen W, Montoto S, Miranda RN, Nanaji NM, Navarro JT, Seegmiller AC, Vose JM, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2011
• Clinicopathological differences between Asian and Western patients with de novo DLBCL treated with R-CHOP
  Sinclair N, Beltran BE, Song MK, Ilic I, Leppa S, Nyman H, Seki R, Uccella S, Li JM, Treaba DO, Butera JN, Castillo JJ, Blood (ASH Annual Meeting Abstracts), 1/1/2011
• A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute...
  Butera JN, Winer ES, Wang C, Castillo JJ, Thomas AG, Safran H, Mega AE, Colvin GA, Rathore B, Quesenberry PJ, Journal of Clinical Oncology, 1/1/2011
• The Immunohistochemical Profile and Other Prognostic Factors In Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with R-CHOP
  Castillo JJ, Beltran B, Chung JS, Ilic I, Leppa S, Seki R, Uccella S, Xia ZG, Butera JN, Blood (ASH Annual Meeting Abstracts), 1/1/2010
• Join now to see all

Lectures

• CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstr_m Macroglobulinemia Treated with Ibrutinib 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Comprehensive Geriatric Assessment in Elderly Patients with Aggressive Non-Hodgkin Lymphoma in Peru 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MY... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom’s Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bing-Neel syndrome: A multi-institutional retrospective study 
  Lugano, Switzerland - 1/19/2015
• ABT-199 triggers apoptosis, and augments ibrutinib cytotoxicity in CXCR4 Wild-type and WHIM mutated Waldenstrom macroglobulinemia cells 
  Lugano, Switzerland - 1/18/2015
• Genomic-based advances in Waldenstrom Macroglobulinemia 
  Figueira da Foz, Portugal - 1/1/2015
• How I treat Waldenstrom Macroglobulinemia 
  Krakow, Poland - 1/1/2015
• Advances in Waldenstrom Macroglobulinemia 
  American University of Beirut Medical Center, Beirut, Lebanon - 1/1/2015
• Novel non-chemotherapeutic options for indolent lymphomas 
  Lima, Peru - 1/1/2015
• The current management of HIV-associated lymphomas 
  Lima, Peru - 1/1/2015
• Survival trends in patients with Waldenstrom Macroglobulinemia 
  London, UK - 1/15/2014
• The role of B-cell receptor inhibitors in lymphoproliferative disorders 
  Ponce, PR - 1/1/2014
• The role of tyrosine kinase inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia, 
  Ponce, PR - 1/1/2014
• Waldenstrom Macroglobulinemia 
  Rhode Island Hospital, Providence, RI - 1/1/2014
• Hyponatremia: Why does it matter for oncology patients? 
  Amsterdam, The Netherlands - 1/1/2013
• Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysi... 
  1/1/2013
• Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysi... 
  Rosemont, IL - 1/1/2013
• Peripheral T-cell lymphoma 
  Roger Williams Medical Center, Boston University School of Medicine, Providence, RI - 1/1/2013
• Join now to see all

Other

• Waldenstrom Macroglobulinemia 
  Castillo JJ, Ghobrial IM, Decision Support in Medicine (TM), Clinical Decision Support: Hematology
  https://www.decisionsupportinmedicine.com
  1/1/2014
• Autoimmune Hemolytic Anemia (including Evans Syndrome) 
  Castillo JJ, Decision Support in Medicine (TM), Clinical Decision Support: Hematology
  https://www.decisionsupportinmedicine.com
  1/1/2013